De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

ANGLE Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Andrew David Newland

Algemeen directeur

UK£281.0k

Totale compensatie

Percentage CEO-salaris	95.7%
Dienstverband CEO	20.6yrs
Eigendom CEO	2.3%
Management gemiddelde ambtstermijn	1.8yrs
Gemiddelde ambtstermijn bestuur	9.3yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Andrew David Newland's beloning veranderd ten opzichte van ANGLE's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-UK£18m
Mar 31 2024	n/a	n/a	-UK£19m
Dec 31 2023	UK£281k	UK£269k	-UK£20m
Sep 30 2023	n/a	n/a	-UK£21m
Jun 30 2023	n/a	n/a	-UK£22m
Mar 31 2023	n/a	n/a	-UK£22m
Dec 31 2022	UK£264k	UK£253k	-UK£22m
Sep 30 2022	n/a	n/a	-UK£19m
Jun 30 2022	n/a	n/a	-UK£17m
Mar 31 2022	n/a	n/a	-UK£16m
Dec 31 2021	UK£446k	UK£242k	-UK£15m
Sep 30 2021	n/a	n/a	-UK£15m
Jun 30 2021	n/a	n/a	-UK£16m
Mar 31 2021	n/a	n/a	-UK£14m
Dec 31 2020	UK£392k	UK£240k	-UK£12m
Jun 30 2020	n/a	n/a	-UK£10m
Mar 31 2020	n/a	n/a	-UK£11m
Dec 31 2019	UK£244k	UK£160k	-UK£11m
Oct 31 2019	n/a	n/a	-UK£10m
Jul 31 2019	n/a	n/a	-UK£9m
Apr 30 2019	n/a	n/a	-UK£9m
Jan 31 2019	n/a	n/a	-UK£9m
Oct 31 2018	n/a	n/a	-UK£8m
Jul 31 2018	n/a	n/a	-UK£8m
Apr 30 2018	UK£336k	UK£229k	-UK£8m

Compensatie versus markt: De totale vergoeding ($USD 373.18K ) Andrew David } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de UK markt ($USD 373.18K ).

Compensatie versus inkomsten: De vergoeding van Andrew David is gestegen terwijl het bedrijf verliesgevend is.

CEO

Andrew David Newland (63 yo)

20.6yrs

Tenure

UK£281,000

Compensatie

Mr. Andrew David William Newland, Meng, ACA founded ANGLE Plc in 1994 and serves as its Group Chief Executive. Mr. Newland founded Provexis, the first ever spin-out of Rowett Institute, Europe’s leading nu...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Andrew David Newland	Founder	no data	UK£281.00k	2.26% £ 602.6k
Ian Griffiths	CFO, Finance Director	7.3yrs	UK£180.00k	0.39% £ 104.9k
Martin Cooke	Director of Operations & Regulatory Affairs	6.8yrs	geen gegevens	geen gegevens
Karen Miller	Chief Scientific Officer	1.8yrs	geen gegevens	geen gegevens
Andrew Holder	Head of Investor Relations	no data	geen gegevens	geen gegevens
Anne-Sophie Pailhes-Jimenez	Head of R&D and Senior Director	less than a year	geen gegevens	geen gegevens
Brett Swansiger	Chief Commercial Officer	1.8yrs	geen gegevens	geen gegevens
Nick Claxton	Senior Vice President of Commercial Operations	1.8yrs	geen gegevens	geen gegevens

1.8yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van AGL wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.8 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Andrew David Newland	Founder	20.6yrs	UK£281.00k	2.26% £ 602.6k
Ian Griffiths	CFO, Finance Director	20.6yrs	UK£180.00k	0.39% £ 104.9k
Harold Swerdlow	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Juliet Thompson	Non-Executive Director	1.8yrs	UK£48.00k	geen gegevens
Ashok Venkitaraman	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Brian Howlett	Non-Executive & Senior Independent Director	11.8yrs	UK£27.00k	0.0031% £ 824.9
Jan Groen	Independent Non-Executive Chairman	5.9yrs	UK£50.00k	geen gegevens
Clive Stanway	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Adrian Newland	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
James Reuben	Member of Scientific Advisory Board	9.3yrs	geen gegevens	geen gegevens
Daniel Danila	Member of Scientific Advisory Board	9.3yrs	geen gegevens	geen gegevens
Greg Shaw	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens

9.3yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van AGL wordt beschouwd als ervaren (gemiddelde ambtstermijn 9.3 jaar).

ANGLE Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

ANGLE plc, Annual General Meeting, Jun 26, 2024

ANGLE plc Announces Senior Management Appointments

ANGLE plc Announces Board Changes

ANGLE plc Announces Appointment of Joseph (Joe) Eid as Non-Executive Director

Insufficient new directors

ANGLE plc Announces Appointment of Juliet Thompson as Non-Executive Director

Recent updates

First half 2024 earnings released: UK£0.029 loss per share (vs UK£0.038 loss in 1H 2023)

Will ANGLE (LON:AGL) Spend Its Cash Wisely?

New minor risk - Financial data availability

ANGLE plc to Report First Half, 2024 Results on Sep 26, 2024

Angle plc Announces the Publication of One of the Company's Clinical Studies That Was Submitted to the FDA for De Novo Regulatory Clearance of the Parsortix PC1 System

New minor risk - Shareholder dilution

Full year 2023 earnings released: UK£0.077 loss per share (vs UK£0.088 loss in FY 2022)

ANGLE plc Provides Revenue Guidance for the First Half of 2024

ANGLE plc to Report Q4, 2023 Results on Jun 07, 2024

ANGLE plc Announces Publication of Study Using the Parsortix System

ANGLE plc, Annual General Meeting, Jun 26, 2024

We're Keeping An Eye On ANGLE's (LON:AGL) Cash Burn Rate

Consensus revenue estimates decrease by 17%

Consensus revenue estimates decrease by 17%

Price target increased by 15% to UK£1.09

Angle plc Announces Use of Parsortix System in Pre-Clinical Model Unlocks Opportunities for Drug Discovery

ANGLE plc Launches Portrait+ CTC Kit At SABCS

Will ANGLE (LON:AGL) Spend Its Cash Wisely?

ANGLE plc Provides Earnings Guidance for the Year 2023

ANGLE plc Announces the Launch of Its Portrait® PD-L1 Test for the Evaluation of PD-L1 Protein Expression on CTCs Following Extensive Development and Optimisation

First half 2023 earnings released: UK£0.038 loss per share (vs UK£0.039 loss in 1H 2022)

Angle plc Announces the Launch of Its Portrait™ Flex Ctc Assay

We Think ANGLE (LON:AGL) Needs To Drive Business Growth Carefully

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

ANGLE plc Announces Senior Management Appointments

ANGLE plc Announces Board Changes

Price target decreased by 35% to UK£0.94

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

We Think ANGLE (LON:AGL) Needs To Drive Business Growth Carefully

ANGLE plc Announces Appointment of Joseph (Joe) Eid as Non-Executive Director

Insufficient new directors

ANGLE plc to Report Fiscal Year 2022 Results on Jun 02, 2023

ANGLE plc Announces Appointment of Juliet Thompson as Non-Executive Director

ANGLE plc Announces the Publication of Results from A Multi-Centre Clinical Study

Angle plc Announces It Presented Results from A Proof of Concept Study At the International Society of Liquid Biopsy Meeting in Miami, Florida

ANGLE plc Announces Streamlining of Operations to Increase Cash Runway

First half 2022 earnings: EPS and revenues miss analyst expectations

ANGLE plc Announces Positive Headline Results from Ovarian Study

ANGLE plc Announces Study Using Parsortix in Head and Neck Cancer

ANGLE plc Announces the Publication of Results from A Clinical Study Undertaken in Partnership with the Wilmot Cancer Institute, University of Rochester, NY, US

Price target increased to UK£2.16

Angle plc Announces New Study Highlights Use of Parsortix System to Enable Cancer Cell Dna Analysis in Non-Small Cell Lung Cancer

ANGLE (LON:AGL) Is In A Good Position To Deliver On Growth Plans

ANGLE plc Announces Ground-Breaking Research by the World-Class Team at the Molecular Oncology Laboratory at the Swiss Federal Institute of Technology Zurich, Switzerland

Angle plc Announces Results of Work Undertaken in Advanced Non-Small Cell Lung Cancer (NSCLC) and Sarcoma Patients

Angle plc Receives FDA Clearance for Parsortix

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Price target increased to UK£1.85

Insufficient new directors

ANGLE plc, Annual General Meeting, Jun 29, 2022

ANGLE plc to Report Fiscal Year 2021 Results on Apr 28, 2022

Angle Announces Parsortix System Shows Potential for Providing Rapid Information on Patient Response to Therapies Targeting Metastasis

ANGLE plc Announces the Edith Cowan University, Perth, Australia, Has Published Results from A Study in Ovarian Cancer Patients Using the Parsortix® System

Price target increased to UK£1.80

ANGLE plc Announces the Publication of Research Undertaken by the World-Class Team At the University of Southern California Norris Cancer Center

ANGLE plc Provides Update on Lab Accreditation and Ovarian Study

Insufficient new directors

First half 2021 earnings released: UK£0.036 loss per share (vs UK£0.02 loss in 1H 2020)

ANGLE plc Announces Parsortix System Demonstrates Ability to Isolate CTCS for Downstream Gene Analysis Revealing Multiple Prognostic Biomarkers

Angle plc Announces That the Health Research Institute of Santiago

CFO, Finance Director exercised options to buy UK£524k worth of stock.

ANGLE (LON:AGL) Is In A Good Position To Deliver On Growth Plans

Founder exercised options and sold UK£1.0m worth of stock

Forecast to breakeven in 2025

ANGLE plc Announces Published Results of A New Study Undertaken in Non-Small Cell Lung Cancer

Angle plc Announces Breakthrough Research Supports Potential Use of Parsortix in Prevention of Relapse of Breast Cancer Patients in Remission

Angle's Parsortix System Harvests Intact CTCs for Whole Genomic Sequencing Identifying Multiple Druggable Targets

We're Not Very Worried About ANGLE's (LON:AGL) Cash Burn Rate